MW 392.5 Da, Purity >99%. Anti-inflammatory glucocorticoid (IC50 = 38 nM and Ki = 6.7 nM for the glucocorticoid receptor). Displays 7-fold higher affinity for glucocorticoid receptors than hydrocortisone. Long-term effects following oral administration. Used in the generation of liver organoids.
50-02-2
> 99%
Solid
392.5 Da
C22H29FO5
5743
Synthetic
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, ABC 35, ABCC 7, ATP Binding Cassette Superfamily C Member 7, ATP binding cassette transporter sub family C member 7, ATP-binding cassette sub-family C member 7, Avian reticuloendotheliosis viral (v rel) oncogene homolog A, BAR, BXR, Bile acid receptor, CF, CFTR/MRP, CFTR_HUMAN, CIMT1, CP2C9_HUMAN, CP2D6_HUMAN, CPC9, CPD6, CYP2C, CYP2C10, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIIC9, CYPIID6, Channel conductance-controlling ATPase, Cholesterol 25-hydroxylase, Cystic Fibrosis Transmembrane Regulator, Cystic fibrosis transmembrane conductance regulator, Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub family C, member 7), Cystic fibrosis transmembrane conductance regulator ATP binding cassette sub family C member 7, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, Cytochrome P450 family 2 subfamily D member 6, Cytochrome P450 family 2 subfamily D polypeptide 6, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-DB1, Debrisoquine 4-hydroxylase, FABP 1, FABPL_HUMAN, FXR, Farnesoid X receptor, Farnesoid X-activated receptor, Farnesol receptor HRR-1, Fatty acid binding protein 1 liver, Fatty acid-binding protein, Fatty acid-binding protein 1, Fatty acid-binding protein liver, GLM1, HRR 1, L-FABP, Liver-type fatty acid-binding protein, MGC131774, MGC149605, MGC88320, Microsomal monooxygenase, NF kappa B p65delta3, NFKB3, NFkB p65, NR1C3, NR1H4_HUMAN, NR1I2_HUMAN, Nuclear factor NF-kappa-B p65 subunit, Nuclear factor kappa-B, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group H member 4, Nuclear receptor subfamily 1 group I member 2, ONR 1, OTTHUMP00000020135, OTTHUMP00000185032, OTTHUMP00000185036, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, OTTHUMP00000233473, OTTHUMP00000233474, OTTHUMP00000233475, OTTHUMP00000233476, OTTHUMP00000233900, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P450 DB1, P450 MP, P450 PB 1, P450C2D, P450IIC9, PAR, PAR q, PPAR-gamma, PPARG1, PPARG2, PPARG_HUMAN, PRR, Peroxisome proliferator activated nuclear receptor gamma variant 1, Peroxisome proliferator activated receptor gamma 1, Peroxisome proliferator-activated receptor gamma, Pregnane X receptor, RIP 14, RXR-interacting protein 14, Retinoid X receptor-interacting protein 14, S-mephenytoin 4-hydroxylase, SXR, Steroid and xenobiotic receptor, TF65_HUMAN, TNR CFTR, Transcription factor NFKB3, Transcription factor p65, V rel avian reticuloendotheliosis viral oncogene homolog A, V rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65, Xenobiotic monooxygenase, cAMP-dependent chloride channel, cytochrome P-450 S-mephenytoin 4-hydroxylase, dJ760C5.1, flavoprotein-linked monooxygenase, nfkappabp65, p65, p65 NF kappaB, p65 NFkB, pregnane X nuclear receptor variant 2, relA, v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)), v rel reticuloendotheliosis viral oncogene homolog A (avian)
MW 392.5 Da, Purity >99%. Anti-inflammatory glucocorticoid (IC50 = 38 nM and Ki = 6.7 nM for the glucocorticoid receptor). Displays 7-fold higher affinity for glucocorticoid receptors than hydrocortisone. Long-term effects following oral administration. Used in the generation of liver organoids.
50-02-2
> 99%
Solid
392.5 Da
C22H29FO5
5743
Synthetic
Crystals; sol in water; max absorption (ethanol): 238-239 nm (e= 14,000); specific optical rotation: +57 deg/D (water); mp 233-235 °C; specific optical rotation: +74 +- 4 deg at 25 °C/D (water- and alc-free basis, 10 mg/mL) /21-phosphate disodium sal. ODORLESS OR HAS SLIGHT ODOR OF ALCOHOL; WHITE, OR SLIGHTLY YELLOW, CRYSTALLINE POWDER; 1 G DISSOLVES IN ABOUT 2 ML OF WATER; INSOL IN DIOXANE; SLIGHTLY SOL IN ALC; INSOL IN ETHER & CHLOROFORM; VERY HYGROSCOPIC /DEXAMETHASONE SODIUM PHOSPHATE/. Solubility in water (25 °C): 10 mg/100 mL; sol in acetone, ethanol, chloroform. In water, 89.0 mg/L at 25 °C.
Dexamethasone
Anti-inflammatory glucocorticoid (IC50 = 38 nM and Ki = 6.7 nM for the glucocorticoid receptor). Displays 7-fold higher affinity for glucocorticoid receptors than hydrocortisone. Long-term effects following oral administration. Used in the generation of liver organoids.
CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
UREBDLICKHMUKA-CXSFZGCWSA-N
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Ambient - Can Ship with Ice
-20°C
It is important to note that this product is reported to be light sensitive, Store in the dark, Store under desiccating conditions
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120743, Dexamethasone, anti-inflammatory glucocorticoid
ab75974 staining p57 Kip2 in HeLa cells treated with dexamethasone (ab120743), by ICC/IF. Increase in p57 Kip2 expression correlates with increased concentration of dexamethasone as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120743 (dexamethasone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab75974 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
1e7 3T3-L1 cells were treated for 15 minutes with 1 µM dexamethasone (ab120743) and 1 µg x mL-1 insulin (Recombinant human Insulin protein (Active) ab123768) with the addition of 50 µM forskolin (Forskolin, Adenylyl cyclase activator ab120058), 0.5 mM IBMX (IBMX, Non-specific cAMP and cGMP inhibitor ab120840) or 0.1 mM 8-CPT-cAMP (8-(4-Chlorophenylthio)adenosine 3',5'-cyclic monophosphate (8-CPT-cAMP), Cell permeable cAMP analog. ab120424), extracted according to the protocol. Lysates were diluted 50-fold, and tested in duplicates (+/-SD).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com